PE20110432A1 - Etexilato de dabigatran o una sal del mismo - Google Patents
Etexilato de dabigatran o una sal del mismoInfo
- Publication number
- PE20110432A1 PE20110432A1 PE2011001003A PE2011001003A PE20110432A1 PE 20110432 A1 PE20110432 A1 PE 20110432A1 PE 2011001003 A PE2011001003 A PE 2011001003A PE 2011001003 A PE2011001003 A PE 2011001003A PE 20110432 A1 PE20110432 A1 PE 20110432A1
- Authority
- PE
- Peru
- Prior art keywords
- dabigatran etexylate
- salt
- same
- etexylate
- dabigatran
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11341308P | 2008-11-11 | 2008-11-11 | |
US23755909P | 2009-08-27 | 2009-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20110432A1 true PE20110432A1 (es) | 2011-07-16 |
Family
ID=41463075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001003A PE20110432A1 (es) | 2008-11-11 | 2009-11-10 | Etexilato de dabigatran o una sal del mismo |
Country Status (21)
Country | Link |
---|---|
US (3) | US20110269799A1 (ar) |
EP (1) | EP2355823A1 (ar) |
JP (1) | JP2013510073A (ar) |
KR (1) | KR20110082564A (ar) |
CN (2) | CN102209546A (ar) |
AR (1) | AR074107A1 (ar) |
AU (1) | AU2009315730A1 (ar) |
BR (1) | BRPI0921354A2 (ar) |
CA (1) | CA2738884A1 (ar) |
CL (1) | CL2011000806A1 (ar) |
CO (1) | CO6382133A2 (ar) |
EA (1) | EA201100755A1 (ar) |
EC (1) | ECSP11011029A (ar) |
IL (1) | IL211853A0 (ar) |
MA (1) | MA32785B1 (ar) |
MX (1) | MX2011004796A (ar) |
NZ (1) | NZ592615A (ar) |
PE (1) | PE20110432A1 (ar) |
TN (1) | TN2011000227A1 (ar) |
TW (1) | TW201031651A (ar) |
WO (1) | WO2010055022A1 (ar) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2358368A1 (en) | 2008-11-11 | 2011-08-24 | Boehringer Ingelheim International GmbH | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy |
PT2550966T (pt) * | 2011-07-25 | 2017-01-31 | Dritte Patentportfolio Beteili | Ésteres de ácido carboxílico de amidoxima de dabigatrana como pró-drogas e utilização das mesmas como medicamento |
US10314594B2 (en) | 2012-12-14 | 2019-06-11 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10307167B2 (en) | 2012-12-14 | 2019-06-04 | Corquest Medical, Inc. | Assembly and method for left atrial appendage occlusion |
US10813630B2 (en) | 2011-08-09 | 2020-10-27 | Corquest Medical, Inc. | Closure system for atrial wall |
WO2014001220A1 (en) | 2012-06-25 | 2014-01-03 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
US20140142689A1 (en) | 2012-11-21 | 2014-05-22 | Didier De Canniere | Device and method of treating heart valve malfunction |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
US9566443B2 (en) | 2013-11-26 | 2017-02-14 | Corquest Medical, Inc. | System for treating heart valve malfunction including mitral regurgitation |
US10842626B2 (en) | 2014-12-09 | 2020-11-24 | Didier De Canniere | Intracardiac device to correct mitral regurgitation |
CN108254216B (zh) * | 2018-03-15 | 2021-04-27 | 攀钢集团西昌钢钒有限公司 | 一种高炉槽的矿料取样方法、装置及可读存储介质 |
US20220175748A1 (en) * | 2019-03-06 | 2022-06-09 | University Of Rochester | Anticoagulant compositions and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6555581B1 (en) * | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
EA200900091A1 (ru) * | 2006-07-17 | 2009-06-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний |
-
2009
- 2009-11-10 CN CN2009801448169A patent/CN102209546A/zh active Pending
- 2009-11-10 TW TW098138140A patent/TW201031651A/zh unknown
- 2009-11-10 CN CN2013102966233A patent/CN103463083A/zh active Pending
- 2009-11-10 BR BRPI0921354A patent/BRPI0921354A2/pt not_active IP Right Cessation
- 2009-11-10 PE PE2011001003A patent/PE20110432A1/es not_active Application Discontinuation
- 2009-11-10 KR KR1020117010632A patent/KR20110082564A/ko not_active Application Discontinuation
- 2009-11-10 WO PCT/EP2009/064874 patent/WO2010055022A1/en active Application Filing
- 2009-11-10 EA EA201100755A patent/EA201100755A1/ru unknown
- 2009-11-10 AU AU2009315730A patent/AU2009315730A1/en not_active Abandoned
- 2009-11-10 MX MX2011004796A patent/MX2011004796A/es not_active Application Discontinuation
- 2009-11-10 NZ NZ592615A patent/NZ592615A/xx not_active IP Right Cessation
- 2009-11-10 EP EP09755873A patent/EP2355823A1/en not_active Withdrawn
- 2009-11-10 JP JP2011535125A patent/JP2013510073A/ja active Pending
- 2009-11-10 US US13/128,460 patent/US20110269799A1/en not_active Abandoned
- 2009-11-10 CA CA2738884A patent/CA2738884A1/en not_active Abandoned
- 2009-11-10 AR ARP090104347A patent/AR074107A1/es unknown
-
2010
- 2010-06-17 US US12/817,369 patent/US20100322870A1/en not_active Abandoned
-
2011
- 2011-03-22 IL IL211853A patent/IL211853A0/en unknown
- 2011-04-12 CL CL2011000806A patent/CL2011000806A1/es unknown
- 2011-05-04 EC EC2011011029A patent/ECSP11011029A/es unknown
- 2011-05-10 TN TN2011000227A patent/TN2011000227A1/fr unknown
- 2011-05-11 MA MA33833A patent/MA32785B1/ar unknown
- 2011-05-11 CO CO11058058A patent/CO6382133A2/es not_active Application Discontinuation
-
2012
- 2012-07-06 US US13/543,080 patent/US20120277269A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2011004796A (es) | 2011-05-30 |
US20100322870A1 (en) | 2010-12-23 |
CN103463083A (zh) | 2013-12-25 |
WO2010055022A1 (en) | 2010-05-20 |
BRPI0921354A2 (pt) | 2019-09-24 |
MA32785B1 (ar) | 2011-11-01 |
TW201031651A (en) | 2010-09-01 |
JP2013510073A (ja) | 2013-03-21 |
CN102209546A (zh) | 2011-10-05 |
US20120277269A1 (en) | 2012-11-01 |
ECSP11011029A (es) | 2011-06-30 |
AR074107A1 (es) | 2010-12-22 |
NZ592615A (en) | 2013-06-28 |
EP2355823A1 (en) | 2011-08-17 |
CL2011000806A1 (es) | 2011-11-11 |
AU2009315730A1 (en) | 2010-05-20 |
TN2011000227A1 (en) | 2012-12-17 |
US20110269799A1 (en) | 2011-11-03 |
EA201100755A1 (ru) | 2011-12-30 |
CO6382133A2 (es) | 2012-02-15 |
CA2738884A1 (en) | 2010-05-20 |
KR20110082564A (ko) | 2011-07-19 |
IL211853A0 (en) | 2011-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20110431A1 (es) | Etexilato de dabigatran o una sal del mismo | |
PE20110432A1 (es) | Etexilato de dabigatran o una sal del mismo | |
CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
CL2010001123A1 (es) | Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07). | |
HRP20220718T1 (hr) | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka | |
CL2012002317A1 (es) | Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras. | |
BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
PE20141906A1 (es) | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento | |
AR062658A1 (es) | Terapias de combinacion para artritis reumatoide | |
CL2013001136A1 (es) | Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional. | |
CL2011000916A1 (es) | Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer. | |
CL2008003798A1 (es) | Compuestos derivados de heterobiciclos aromaticos sustituidos, inhibidores de pi3 quinasa; composicion farmaceutica; utiles en el tratamiento de cancer, melanomas, glioblastomas, entre otras enfermedades. | |
GT200600028A (es) | Compuestos y composiciones como inhibidores de proteina kinasa | |
AR060019A1 (es) | Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo | |
EA201071378A1 (ru) | Дронедарон для предотвращения постоянной фибрилляции предсердий | |
CR9425A (es) | Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo | |
UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
CL2008003201A1 (es) | Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno. | |
EA201101231A1 (ru) | Способы предотвращения или снижения риска смертности | |
CL2011000805A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular. | |
PE20170469A1 (es) | Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontano que utilizan composiciones de udenafilo | |
MX2016007682A (es) | Composicion farmaceutica que comprende ivabradina amorfa. | |
AR072954A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona, producto de fabricacion y envase | |
CL2016002655A1 (es) | Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
AR068608A1 (es) | Neramexano para el tratamiento de nistagmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |